MedTrace Logo

Cyclobenzaprine for Postoperative Pain in Minimally Invasive Hysterectomy

NCT07664956 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-06-24

No results posted yet for this study

Summary

Typical postoperative pain control after minimally invasive hysterectomy includes ibuprofen, acetaminophen, and a short course of narcotics. The purpose of this study is to see if adding cyclobenzaprine to this regime improves pain control and lessens narcotic use.

Conditions

  • Minimally Invasive Surgical Procedures
  • Abnormal Uterine Bleeding, Unspecified
  • Adenomyosis of Uterus
  • Fibroid Uterus
  • Chronic Pelvic Pain
  • Endometriosis
  • Menorrhagia
  • Endometritis
  • Adnexal Diseases

Interventions

DRUG

Cyclobenzaprine

5mg cyclobenzaprine q8hr for one week postoperatively after minimally invasive hysterectomy

Sponsors & Collaborators

  • Christiana Care Health Services

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2026-09-01
Completion
2026-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07664956 on ClinicalTrials.gov